Generate a tailored SOP for Dr. Dipanjan Chowdhury. Improve your application with a focused, well-structured draft.
Dipanjan Chowdhury is a Professor in the Department of Radiation Oncology at Harvard Medical School. His research focuses on understanding the mechanisms of DNA double-strand break (DSB) repair, which is critical for maintaining genomic stability and cell health. He investigates the mechanistic pathways of DSBs including homologous recombination (HR) and non-homologous end joining (NHEJ), which determine the cell's response to DNA damage. His work has revealed that the competition between these pathways varies among different cell types and phases of the cell cycle, which has significant implications for cancer therapy. Notably, he has explored how the loss of various DNA repair proteins, such as BRCA1, can influence tumor sensitivity to therapies like poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based drugs. Additionally, Chowdhury has conducted extensive research on microRNAs that modulate DSB repair proteins, impacting therapeutic outcomes for patients with BRCA1-deficient tumors. His innovative use of CRISPR-Cas9 technology has greatly advanced the understanding of genetic factors that restore DSB repair mechanisms in cancer cells. Through his research, he aims to uncover the intricate biological pathways involved in DSB repair and their therapeutic potential in oncology.
Administered by the Division of Medical Sciences (DMS). GRE is not required and will not be considered for BBS, Immunology, and Neuroscience.